Research Analysts Offer Predictions for FMS Q1 Earnings

Fresenius Medical Care AG (NYSE:FMS) – Stock analysts at Zacks Research lifted their Q1 2025 earnings estimates for Fresenius Medical Care in a research report issued on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will post earnings of $0.44 per share for the quarter, up from their prior estimate of $0.39. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Fresenius Medical Care’s Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $2.01 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.49 EPS, Q3 2026 earnings at $0.60 EPS, FY2026 earnings at $2.19 EPS and FY2027 earnings at $2.07 EPS.

A number of other research firms have also recently issued reports on FMS. StockNews.com raised Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Finally, Truist Financial boosted their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Monday, January 6th.

Fresenius Medical Care Trading Down 1.4 %

Shares of NYSE:FMS opened at $24.29 on Thursday. The firm has a fifty day moving average of $23.86 and a two-hundred day moving average of $22.34. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Fresenius Medical Care has a 12-month low of $17.93 and a 12-month high of $25.25. The firm has a market capitalization of $14.25 billion, a P/E ratio of 20.07, a price-to-earnings-growth ratio of 0.76 and a beta of 0.99.

Institutional Investors Weigh In On Fresenius Medical Care

A number of large investors have recently bought and sold shares of FMS. Forum Financial Management LP acquired a new stake in shares of Fresenius Medical Care in the fourth quarter worth about $247,000. Vident Advisory LLC increased its holdings in shares of Fresenius Medical Care by 11.8% during the 4th quarter. Vident Advisory LLC now owns 23,410 shares of the company’s stock valued at $530,000 after acquiring an additional 2,464 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in Fresenius Medical Care in the 4th quarter worth approximately $290,000. Point72 Asset Management L.P. bought a new stake in Fresenius Medical Care during the fourth quarter worth approximately $850,000. Finally, Quantinno Capital Management LP boosted its position in Fresenius Medical Care by 16.0% during the fourth quarter. Quantinno Capital Management LP now owns 127,726 shares of the company’s stock worth $2,892,000 after purchasing an additional 17,648 shares during the period. 8.37% of the stock is currently owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.